Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IDVYNSO vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Treatment of schizophrenia,Adjunctive treatment of major depressive disorder
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Primarily hepatic via CYP3A4 and CYP2D6
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Approximately 85% bound, primarily to albumin and α1-acid glycoprotein.
47% bound to human plasma proteins, primarily albumin.
Vd = 1.5–2.5 L/kg, indicating extensive tissue distribution.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Oral: 75–85% (first-pass effect minimal); intravenous: 100%.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59: 2.5 mg/kg IV once daily for 28 days. Cr Cl < 30: not recommended.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: 2.5 mg/kg IV once daily for 28 days. Child-Pugh C: not recommended.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Not approved for pediatric use. Safety and efficacy not established.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment required; monitor renal function due to age-related decline. Use lowest effective dose.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
None
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
May cause QT prolongation; monitor ECG. Risk of extrapyramidal symptoms. Caution in patients with hepatic impairment.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Concurrent use with strong CYP3A4 inducers. History of QT prolongation or torsade de pointes.
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
Avoid tyramine-rich foods: aged cheeses, cured meats (e.g., salami, pepperoni), fermented foods (e.g., sauerkraut, kimchi), soy products, broad bean pods, draft beers, and red wine. Tyramine can cause hypertensive crisis when combined with IDVYNSO.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. Contraindicated in pregnancy.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants; discontinue breastfeeding or discontinue drug.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No dose adjustment recommended; use is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance and volume of distribution) may require dosage increase if used for life-threatening conditions, but alternative therapy is preferred.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
IDVYNSO is a reversible inhibitor of monoamine oxidase A (RIMA); avoid concurrent use with sympathomimetics and tyramine-rich foods. Monitor for hypertensive crisis; discontinue 5 days before elective surgery. Use with caution in patients with hepatic impairment.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
Do not take with other antidepressants, especially MAOIs, SSRIs, or SNRIs.,Avoid foods high in tyramine such as aged cheeses, cured meats, and fermented products.,Report sudden severe headache, palpitations, or chest pain immediately.,Take with food to minimize nausea; do not crush or chew tablets.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IDVYNSO vs CLOLAR, answered by our medical review team.
IDVYNSO is a Antineoplastic Agent that works by IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IDVYNSO and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IDVYNSO is: 5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IDVYNSO and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IDVYNSO is classified as Category C. Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimesters: risk of . CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.